AXIM Biotechnologies has developed the next-generation version of its Covid-19 Rapid Neutralizing Antibody Test.
The company’s first rapid test is currently under review by the US Food and Drug Administration (FDA).
Antiviral antibodies are easy to detect and measure using a drop of blood.
If levels of neutralising antibodies in the blood are high enough, they protect individuals from Covid-19 infection.
Covid-19 vaccines are developed to induce antibodies against SARS-CoV-2 virus to prevent infection. However, not all antibodies neutralise the virus and provide protection from the disease.
AXIM’s rapid test distinguishes between the antibodies that bind and neutralise the SARS-CoV-2 virus and the antibodies that bind to the virus but do not neutralise it.
The latest version of the rapid neutralising antibody test shows users if they respond to the Covid-19 vaccine they receive.
It also provides a semi-quantitative analysis regarding their neutralising antibody levels in a single test.
AXIM Biotechnologies CEO John Huemoeller II said: “This new test is extremely important because it helps people know if they are protected after receiving the vaccine in just ten minutes.
“People want to make sure they are protected as vaccine immunity wanes so that they don’t develop an asymptomatic infection and transmit the virus to vulnerable populations.”
The AXIM neutralising antibody test for Covid-19 is claimed to be the first rapid test that measures the levels of functional neutralising antibodies providing protection against the SARS-CoV-2 virus.
Additionally, AXIM stated that it is developing rapid diagnostic tests to detect cancer and ophthalmological conditions, such as dry eye disease (DED), in the early stage.